We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+4.35%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$7.24B
AUM Growth
+$171M
Cap. Flow
+$215M
Cap. Flow %
2.98%
Top 10 Hldgs %
34.84%
Holding
226
New
18
Increased
74
Reduced
41
Closed
9

Top Buys

Rank Stock Value
1
RLAY icon
Relay Therapeutics
RLAY
+$49.6M
2
EXAS
Exact Sciences
EXAS
+$26.3M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$25.9M
4
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$24.6M
5
MTEM
Molecular Templates, Inc.
MTEM
+$18.3M

Top Sells

Rank Stock Value
1
HALO icon
Halozyme
HALO
+$35.1M
2
PACB icon
Pacific Biosciences
PACB
+$25.7M
3
EVH icon
Evolent Health
EVH
+$20.6M
4
AKCA
Akcea Therapeutics Inc
AKCA
+$15.9M
5
MDT icon
Medtronic
MDT
+$14.7M

Sector Composition

Rank Sector Weight
1 Healthcare 95.98%
2 Industrials 0.6%
3 Technology 0.53%
4 Communication Services 0.41%
5 Financials 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MNTA
226
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
– –
-74,400
Closed -$2.48M
6 7 8 9
10

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2020 Portfolio in Review

As of Q3 2020, Bellevue Group held 226 positions worth $7.24B, up 2.4% from $7.07B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Bellevue Group's Q3 2020 filing shows 18 new, 74 increased, 41 reduced and 9 closed positions. Its largest new stake was Relay Therapeutics: 1,300,000 shares worth $55.4M. The largest sale was Halozyme, an estimated $35.1M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q3 2020 buy was Relay Therapeutics: 1,300,000 shares worth $55.4M.
  • Bellevue Group added most to Ionis Pharmaceuticals in Q3 2020, an estimated $25.9M increase.
  • Bellevue Group's biggest Q3 2020 reduction was Halozyme, cutting an estimated $35.1M.
  • Bellevue Group fully exited BioMarin Pharmaceuticals in Q3 2020, selling an estimated $9.48M.
  • Bellevue Group's ten largest holdings make up 35% of its $7.24B portfolio in Q3 2020.
  • Bellevue Group opened 18 new positions and closed 9 in Q3 2020.
  • Bellevue Group's portfolio value rose 2.4% quarter-over-quarter to $7.24B.

Based on Bellevue Group's 13F filing for Q3 2020, filed 16 Nov 2020.